Sarepta Therapeutics Inc. | Mutual Funds
Mutual Funds that own Sarepta Therapeutics Inc.
T Rowe Price Health Sciences Fund
1,611,512
2.42%
303,312
1.74%
06/30/2018
Vanguard Small Cap Index Fund
1,566,266
2.36%
23,250
0.22%
07/31/2018
Vanguard Total Stock Market Index Fund
1,561,929
2.35%
1,582
0.03%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,474,403
2.22%
0
2.21%
07/31/2018
T Rowe Price New Horizons Fund
1,431,964
2.15%
300,300
0.81%
06/30/2018
Fidelity Select Health Care Portfolio
1,349,471
2.02%
59,471
2.45%
07/31/2018
Vanguard Small Cap Growth Index Fund
894,284
1.35%
13,279
0.48%
07/31/2018
Prudential Jennison Health Sciences Fund
821,050
1.24%
0
4.44%
07/31/2018
Vanguard Extended Market Index Fund
816,752
1.23%
900
0.16%
07/31/2018
BlackRock Health Sciences Opportunities Portfolio
772,755
1.15%
0
1.49%
06/29/2018
| Address |
215 First Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.sareptatherapeutics.com |
| Updated |
07/08/2019 |
| Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. |
